11-19 更新 实时
首页/ 科技公司/ 正文

Science Corporation 获新融资,估值达 35 亿美元

科技公司 来源:TechCrunch AI 2026-11-17 22:26 0 阅读 机器翻译
Science Corporation 获新融资,估值达 35 亿美元

Science Corporation 是由前 Neuralink 总裁 Max Hodak 于 2021 年创立的医疗科技初创公司。该公司在一篇博客文章中表示,其完成了 4 亿美元的 D 轮融资。

一位熟悉交易的人士告诉 TechCrunch,新一轮投资者对公司的估值为 35 亿美元。这些投资方包括 Khosla Ventures、Ackman Oxman Institute、Tenet Healthcare、885 Capital、Y Combinator 和 PLC Neurotech。

Hodak 在大学时靠说服他人进入了一个神经科学研究生实验室,此后一直投身生物技术。他联合创立了 Science,旨在利用新技术来理解大脑并与大脑互动。

Science 的首款产品是 PRIMA,一种可穿戴且可植入的芯片,帮助年龄相关性黄斑变性患者恢复部分视力。该设备已在欧洲获批并在德国上市,同时正在针对新适应症开展试验。

Hodak 在 TechCrunch Disrupt 台上宣布,该设备目前正在另一种致盲疾病——Stargardt 病患者中开展试验。

借助这笔融资,该公司旨在通过 FDA 的人道主义器械豁免(Humanitarian Device Exemption)将该设备引入美国;该豁免允许实验性医疗技术用于治疗罕见疾病。Science 已说服 FDA,双眼晚期黄斑变性足够罕见,因此允许他们寻求批准在美国人群中使用该设备。

不过,这家初创公司更大的抱负和创立初衷,是通过一种由培养神经元与硅结合而成的生物混合传感器,直接与人类大脑相连。该公司目前正与耶鲁大学神经外科教授 Murat Günel 一起设计该设备的首次人体试验。Günel 对 TechCrunch 表示,该设备有望为帕金森病以及其他脑损伤和脑部疾病提供潜在疗法。

生物科技与健康最新动态

译文由英文原文机器翻译,术语按行业惯例统一,可在文末展开原文核对。

查看英文原文(Science Corporation’s brain tech is worth $3.5 billion after new funding)

Science Corporation’s brain tech is worth $3.5 billion after new funding

Science Corporation, the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post.

Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.

Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.

Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.

With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let them seek approval to use the device on people in the US.

Still, the startup’s big ambition and founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses.

Latest in Biotech & Health

原文为英文,正文由自动抓取并保留原文。

本文由采集器自动同步

原文发布于 TechCrunch AI(Science Corporation’s brain tech is worth $3.5 billion after new funding),标题、摘要与正文由机器翻译,术语按行业惯例统一,未经人工逐句校订。

阅读原文 ↗